A large study may bring us closer to identifying interventions that can help the homeless population with neurologic disease.
Findings from a new study may be especially useful for PD patients who lack easy access to neurologists, especially those who are mobility impaired or live in remote areas.
In this podcast, Heidi Moawad, MD interviews Cesar Ochoa-Lubinoff, MD, MPH, FAAP, about recent encouraging clinical trial results in patients with Angelman syndrome.
Two medical students who are conservatory-trained musicians describe a memorable performance at a center for older adults with dementia.
This podcast discusses preliminary evidence about the effects of karate on quality of life and several measures of gait, balance, and mobility in patients with PD.
Pain related to more severe motor symptoms, phosphodiesterase 10A loss seen early, novel therapy shows promise, and other recent findings are summarized here.
What’s in your differential diagnosis for this cachectic, disheveled patient who can no longer carry on a coherent conversation?
Alzheimer and circulating cholesterol linked, obesity has a big impact on MS, mild traumatic brain injury difficulties persist, and other recent findings are summarized here.
Does the clinical picture point to a reaction to alcohol? A food allergy? What do you suspect is the likely culprit?
Emgality (galcanezumab-gnlm) is the first FDA-approved drug that reduces the frequency of headache attacks.
Are his symptoms related to a fall that occurred 2 years earlier at work?
15-Month-Old Baby With Delayed Communication and Social Milestones: Can Autism Be Reliably Diagnosed?
Current recommendations suggest screening for autism starting at 18 months, but parents are increasingly anxious about their children and a possible diagnosis.
College athletes may be sabotaging their careers—as well as their performance—when they sacrifice sleep for sports, studying, and socializing.
A new tool to add to your armamentarium?
What’s new in MS: teratogenicity of disease-modifying drugs, extended interval natalizumab dosing, a potential biomarker, the “MS hug,” and virtual reality therapy.